Details of the Drug

General Information of Drug (ID: DMUMOEV)

Drug Name
Ansuvimab
Indication
Disease Entry ICD 11 Status REF
Ebola virus infection 1D60.0 Approved [1]
Affected Organisms
Zaire ebolavirus (strain Mayinga-76)
ATC Code
J06BD04: Ansuvimab
J06BD: Antiviral monoclonal antibodies
J06B: IMMUNOGLOBULINS
J06: IMMUNE SERA AND IMMUNOGLOBULINS
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Antibody
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 1480 +/- 304 mgday/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 198.45 +/- 45.15 mg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3.21 +/- 1.56 h [2]
Clearance
The clearance of drug is 115 +/- 15 mL/day [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 20.1 +/- 6.9 days (a single adminutesistration of 5 mg/kg), and 26.7 +/- 3.8 (a single adminutesistration of 10 mg/kg) [2]
Metabolism
The drug is metabolized via various proteolytic and catabolic processes within the body []
Vd
The volume of distribution (Vd) of drug is 5.08 +/- 0.88 L [2]
Cross-matching ID
UNII
TG8IQ19NG2
DrugBank ID
DB16385
TTD ID
DRM1X5

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ebola virus Envelope glycoprotein (EV GP) TT2F0AU VGP_EBOZM Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24.